NASDAQ · OPK

Opko Health Inc.

$1.24 +$0.02 (+1.64%) 1D After hours
Session Pulse After hours 1 mentions on Mon No new SEC filings since Tue close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$921.21M
Market cap
—
P/E · TTM
$581.12M
Revenue · TTM
−$212.92M
Net income
EPS · TTM $-0.32
Dividend yield —
Free cash flow −$174.22M
Beta · 1Y 0.92
EBITDA · TTM −$10.92M
Gross margin 36.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    A material event was filed (Form 8-K).

    8-K - OPKO HEALTH, INC. (0000944809) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 13
    The stock moved -8.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 13
  • May 28
    The stock moved +10.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 28

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$921.21M
Enterprise value$582.36M
Shares outstanding755.1M
52-wk range$0.98 – $1.61
Avg volume · 20D4.3M
Net cash $338.86M
Book value / share$1.79
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Opko Health Inc.
IPO dateNov 2, 1995
Employees2275

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S1.59
P/FCF—
EV/EBITDA—
EV/Sales1.00
Graham №—

Profitability

Gross 36.0%
Operating -17.4%
Net -36.6%
FCF -30.0%
ROE / ROIC -17.7% · -10.7%

Financial Health

Current ratio3.61
Quick ratio3.17
Debt / equity0.00
Debt / EBITDA -0.32
Net cash $338.86M
Working capital$386.98M

Cash Flow · TTM

Operating CF −$163.30M
Capex −$10.92M
Free cash flow −$174.22M
Buybacks $51.81M
Dividends paid —
Shareholder yield 5.6%

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-0.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings